Geron (GERN) Stock: Buy, Sell, or Hold?
GERN - Geron Corp
$1.20
-0.01 (-0.83%)
▼
5d:
-4.76%
30d:
-24.53%
90d:
-16.67%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 29, 2026 at $1.24 · last confirmed Oct 1, 2026
Strength: 7.7/10
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GERN trades at premium valuation expecting 7.1% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: GERN trades at premium valuation expecting 7.1% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.20, which is considered oversold relative to its 30-day fair value range of $1.25 to $1.50. From a valuation perspective, the stock is trading at a premium (Forward PE: 30.2) compared to its historical average (24.6). At these levels, the market is pricing in 7.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GERN is in a downtrend. The price is currently testing key support at $1.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.25 (+251.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GERN is in a downtrend. The price is currently testing key support at $1.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.25 (+251.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.25 -
$1.50
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.6%
Protect Your Profits
Holding GERN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 251.2% below Wall St target ($4.25)
- NEUTRAL: Trading at premium valuation - market expects 7.1% growth which is achievable
- NEUTRAL: Bottoming setup forming (53/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$1.25 -
$1.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.19
Resistance Level
$1.33
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.25
Wall Street Target
$4.25
(+251.2%)
Revenue Growth (YoY)
17.2%
Profit Margin
-33.1%
Valuation Premium vs History
+7.1% premium
PE vs Historical
30.3 vs 24.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.1%
(market-implied from PE analysis)
1-Year Target
$1.30
(+7%)
2-Year Target
$1.39
(+15%)
3-Year Target
$1.49
(+23%)
3-Yr Target (if PE normalizes)
(PE: 30→25)
PE COMPRESSION
$1.21
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 02, 2026 3:59 PM ET
Data refreshes hourly during market hours. Next update: 4:59 PM
Data refreshes hourly during market hours. Next update: 4:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 51 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
